AstraZeneca's Imfinzi shows positive results for endometrial cancer patients
AstraZeneca
9,990.00p
15:45 15/11/24
AstraZeneca said results from a Phase III trial showed its Imfinzi treatment in combination with chemotherapy showed a significant improvement in patients with endometrial cancer.
FTSE 100
8,060.61
15:45 15/11/24
FTSE 350
4,453.56
15:45 15/11/24
FTSE All-Share
4,411.85
15:45 15/11/24
Pharmaceuticals & Biotechnology
19,259.77
15:45 15/11/24
The pharmaceutical company said the drug, followed by either Imfinzi plus its Lynparza drug or Imfinzi alone as maintenance therapy showed a “statistically significant and clinically meaningful" improvement in progression-free survival compared to chemotherapy alone in patients with newly diagnosed advanced or recurrent endometrial cancer.
“There was a greater clinical benefit observed with the combination of of Imfinzi and Lynparza as maintenance treatment,” it added.
Endometrial cancer is a highly heterogenous disease that originates in the tissue lining of the womb and is most common in women who have already been through the menopause, with the average age at diagnosis being over 60 years old.
Reporting by Frank Prenesti for Sharecast.com